Clinical trials: Progressive Multiple Sclerosis
Multiple Sclerosis
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
This was a retrospective cohort study using the electronic medical record (EMR) database from Cleveland Clinic. The data was analyzed at start of ofatumumab (OMB) therapy (baseline, defined as 6 months prior to OMB initiation)…
- Trial name
- NCT06737419
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS)
A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
The goal of the ALLNEW clinical trial is to learn if CTA313 UCART is safe and effective for patients with immune mediated disorders.
- Conditions
- Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS), Autoimmune Encephalitis
- Trial name
- ALLNEW (NCT07783269)
- Testing
- CTA313 UCAR T Cell Infusion
- Volunteers
- 81 people
- Sponsor
- Imviva Bio
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. MS, typical presents with progression of clinical symptoms which mainly include motor and cognitive impairment, as well as…
- Trial name
- NCT06436131
- Testing
- In-phase Bilateral Exercise, Conservative exercises
- Where
- Cyprus
- Volunteers
- 20 people
- Sponsor
- Cyprus University of Technology
Multiple Sclerosis
Assessment of Synaptic Density in MS
The investigators propose to use the novel SV2a-PET ligand, [F-18]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive…
- Trial name
- NCT04634994
- Testing
- [F-18]SDM-8
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Multiple Sclerosis
Remote Ischemic Conditioning in PPMS
Progressive MS remains the most difficult therapeutic challenge. Remyelination is a promising therapeutic strategy but an effective pharmacologic intervention remains elusive.
- Trial name
- NCT06171334
- Testing
- Remote ischemic conditioning
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Calgary
Progressive Multiple Sclerosis
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
The goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression.
- Trial name
- NCT06451159
- Testing
- KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bruce Cree
Multiple Sclerosis
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
- Trial name
- NCT02601885
- Testing
- ABT-555
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie
Multiple Sclerosis
Effects of Ten-Weeks Progressive Resistance Training on Neuromuscular Performance, Mobility, Heart Rate Variability and Sleep Quality in Persons With Multiple Sclerosis
Multiple Sclerosis (ME) is a degenerative, inflammatory and autoimmune demyelinating disease of the central nervous system, characterized by demyelination due to inflammation and degeneration of the myelin sheaths enveloping…
- Trial name
- NCT04452760
- Testing
- Physical exercise, Testing sessions
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Universidad Católica San Antonio de Murcia